0
Abstract: Slide Presentations |

EFFECT OF CONTINUOUS POSITIVE AIRWAY PRESSURE TREATMENT ON SERUM ADIPONECTIN LEVEL AND MEAN ARTERIAL PRESSURE IN MALE PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME FREE TO VIEW

Zhang Xilong, PhD*; Yin Kaisheng, MD
Author and Funding Information

1st Affiliated Hospital of Nanjing Medical University, Nanjing, Peoples Rep of China



Chest. 2006;130(4_MeetingAbstracts):130S. doi:10.1378/chest.130.4_MeetingAbstracts.130S-c
Text Size: A A A
Published online

Abstract

PURPOSE: Recent research suggested that obstructive sleep apnea syndrome (OSAS) might be independently associated with hyponectinemia, which was linked to some complications of OSAS, such as hypertension, diabetes, etc. This study was conducted to investigate the effect of continuous positive airway pressure (CPAP) treatment on bilateral changes of serum adiponectin levels and mean arterial pressure and their possible links in male OSAS patients.

METHODS: 23 adult male patients with moderate or severe OSAS but without obesity, coronary heart disease and diabetes were recruited. Their blood samples were collected and morning mean arterial pressure (MAP) was measured before CPAP treatment and on day 3, 7, 14 of CPAP treatment respectively. The serum adiponectin concentration was tested with radioimmunoassay.

RESULTS: Compared with the serum adiponectin level before CPAP treatment, no significant change was found in OSAS patients on day 3 and day 7 of CPAP treatment (P>0.05). It was not until day 14 of CPAP treatment did a significant elevation in serum adiponectin level occur (P<0.01). Meanwhile, the MAP showed no statistically different among its levels before CPAP, on day 3 and day 7 of CPAP treatment (P>0.05). However, on day 14 of CPAP treatment, a significant lower MAP than before treatment was observed (P<0.05).

CONCLUSION: Compared with the serum adiponectin level before CPAP treatment, no significant change was found in OSAS patients on day 3 and day 7 of CPAP treatment (P>0.05). It was not until day 14 of CPAP treatment did a significant elevation in serum adiponectin level occur (P<0.01). Meanwhile, the MAP showed no statistically different among its levels before CPAP, on day 3 and day 7 of CPAP treatment (P>0.05). However, on day 14 of CPAP treatment, a significant lower MAP than before treatment was observed (P<0.05).

CLINICAL IMPLICATIONS: Hypoadiponectinemia may be involved in pathogenesis of hypertension in OSAHS patients. The effectiveness of CPAP treatment for hypertension in patients with OSAHS may be related to its reversal efficacy on hypoadiponectinemia in them.

DISCLOSURE: Zhang Xilong, None.

Tuesday, October 24, 2006

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543